Research
Energy balance
Further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists.
Practitioners should be aware that while glucagon and GLP-1 co-agonists show promise, more research is needed before widespread clinical application.
StrongQualifiesmedium confidence
Prior to clinical use, however, further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists.
Why this rating
The claim is based on the need for further validation in clinical settings.
Source
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone et al. · Peptides · 2024
DOI 10.1016/j.peptides.2024.171219
otherCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →